Hence, the CRC syngeneic mouse model was employed to further assess the efficacy of NSUN2 inhibitor in combination with PD‐1 blockades, and the encouraging results supported the potential ability of NSUN2 for cancer immunotherapy in CRC. The gene discussed is NSUN2; the disease is colorectal carcinoma.